---
title: "CJC-1295 (no DAC) + Ipamorelin"
canonical_url: https://peptidelibrary.app/library/cjc-1295-ipamorelin
description: "Research blend combining a GHRH analog (usually Mod GRF / CJC no DAC) with ipamorelin to stimulate GH via two receptor classes. Not FDA-approved. Both components are WADA S2."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# CJC-1295 (no DAC) + Ipamorelin

CJC-1295 (no DAC) + Ipamorelin, also called CJC / Ipamorelin blend or GHRH + GHS stack, is a research peptide in the GHRH/GHRP class. This combination pairs a GHRH receptor agonist with a ghrelin receptor agonist, which is pharmacologically distinct from combining two agents of the same class.

Research blend combining a GHRH analog (usually Mod GRF / CJC no DAC) with ipamorelin to stimulate GH via two receptor classes. Not FDA-approved. Both components are WADA S2.

Also known as: CJC / Ipamorelin blend, GHRH + GHS stack.

Categories: Fat Loss, Muscle/Recovery, Experimental.

## Classification

- Type: GHRH + GHS combination
- Mechanism class: GHRH/GHRP
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

This combination pairs a GHRH receptor agonist with a ghrelin receptor agonist, which is pharmacologically distinct from combining two agents of the same class. CJC-1295 without DAC binds the GHRH receptor on somatotrophs and raises cyclic AMP, increasing growth hormone synthesis and release, while ipamorelin binds growth hormone secretagogue receptor 1a and additionally reduces hypothalamic somatostatin tone. Because the two receptors converge on growth hormone release through separate signalling routes and somatostatin inhibition is relieved at the same time, the combined effect reported in experimental settings exceeds the sum of either alone. No controlled human trials of this specific blend have been published.

Targets: GHRH receptor, GHSR (ghrelin receptor).

Origin: Combination of two synthetic GH secretagogues.

## Properties

- Sequence: CJC: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2; Ipa: Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Molecular formula: Varies (blend)
- Molecular weight: Varies
- CAS number: N/A (blend)
- Half-life: CJC: ~30 min; Ipa: ~2 hours

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: None documented
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. 2006. Human study (early or uncontrolled). Population: Healthy adults aged 21–61. Growth hormone rose 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9–11 days after one injection; estimated half-life 5.8–8.1 days. Research on a related compound, not this one. Limitations: Studied an analog, not CJC-1295 (no DAC) + Ipamorelin itself [Source](https://pubmed.ncbi.nlm.nih.gov/16352683/)
2. Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. 1999. Human study (early or uncontrolled). Population: Healthy male volunteers, 8 per dose level. Dose-proportional pharmacokinetics, terminal half-life about 2 hours, and a single episode of growth hormone release at every dose. Research on a related compound, not this one. Limitations: Studied an analog, not CJC-1295 (no DAC) + Ipamorelin itself [Source](https://pubmed.ncbi.nlm.nih.gov/10496658/)
3. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus. Int J Colorectal Dis. 2014. 2014. Human study (early or uncontrolled). Population: Adults after small or large bowel resection (117 enrolled, 114 analysed). No significant difference from placebo in time to first tolerated solid meal (p = 0.15). Research on a related compound, not this one. Limitations: Studied an analog, not CJC-1295 (no DAC) + Ipamorelin itself [Source](https://pubmed.ncbi.nlm.nih.gov/25331030/)

## Safety

Side effects: Flushing; Headache; Water retention.

Risks: Desensitization; Banned in sports.

Contraindications: Cancer history.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

CJC-1295 (no DAC) + Ipamorelin is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is CJC-1295 (no DAC) + Ipamorelin?

Research blend combining a GHRH analog (usually Mod GRF / CJC no DAC) with ipamorelin to stimulate GH via two receptor classes. Not FDA-approved. Both components are WADA S2.

### How does CJC-1295 (no DAC) + Ipamorelin work?

This combination pairs a GHRH receptor agonist with a ghrelin receptor agonist, which is pharmacologically distinct from combining two agents of the same class. CJC-1295 without DAC binds the GHRH receptor on somatotrophs and raises cyclic AMP, increasing growth hormone synthesis and release, while ipamorelin binds growth hormone secretagogue receptor 1a and additionally reduces hypothalamic somatostatin tone.

### Is CJC-1295 (no DAC) + Ipamorelin FDA approved?

No. CJC-1295 (no DAC) + Ipamorelin is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of CJC-1295 (no DAC) + Ipamorelin?

Reported half-life for CJC-1295 (no DAC) + Ipamorelin is CJC: ~30 min; Ipa: ~2 hours. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of CJC-1295 (no DAC) + Ipamorelin?

CJC-1295 (no DAC) + Ipamorelin has the sequence CJC: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2; Ipa: Aib-His-D-2-Nal-D-Phe-Lys-NH2, giving a chain of 36 amino acids. Its molecular formula is Varies (blend).

### Is CJC-1295 (no DAC) + Ipamorelin banned in sport?

CJC-1295 (no DAC) + Ipamorelin is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [Component evidence (Ipamorelin) — The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus](https://pubmed.ncbi.nlm.nih.gov/38996787/)
- [Component evidence (Ipamorelin) — The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism](https://pubmed.ncbi.nlm.nih.gov/39043357/)
